Sreenivas Katragadda, MD
Child & Adolescent Psychiatry · Manchester, NHNPI 1972698850
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 330 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 37.3% of the total. Reporting peaked in 2019 at $1,751 and has fallen 93.8% since, to $109 in 2025.
Across 330 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$448
- Sunovion Pharmaceuticals Inc.$303
- Neos Therapeutics, LP$296
- Lundbeck LLC$271
- Johnson & Johnson$219
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,96999%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 138 | $1,864 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $448 |
| Sunovion Pharmaceuticals Inc. | 23 | $303 |
| Neos Therapeutics, LP | 20 | $296 |
| Lundbeck LLC | 21 | $271 |
| Johnson & Johnson | 10 | $219 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $219 |
| Vanda Pharmaceuticals Inc. | 11 | $202 |
| Axsome Therapeutics, Inc. | 2 | $165 |
| Alkermes, Inc. | 6 | $161 |
| Otsuka America Pharmaceutical, Inc. | 10 | $159 |
| Shire North American Group Inc | 18 | $113 |
| Supernus Pharmaceuticals, Inc. | 6 | $111 |
| Neurocrine Biosciences, Inc. | 6 | $110 |
| Tris Pharma Inc | 5 | $89 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Merck | 3 | $45 |
| Ironshore Pharmaceuticals Inc. | 3 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Almatica Pharma LLC | 2 | $30 |
| Bausch Health US, LLC | 2 | $27 |
| Alfasigma USA, Inc. | 1 | $18 |
| Corium, LLC | 1 | $13 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$109
How this compares
Too few child & adolescent psychiatry providers in New Hampshireto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 29 | $15,239 |
| Lurasidone Hcl | 25 | $12,732 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 52 | $6,336 |
| CymbaltaDuloxetine Hcl | 11 | $5,959 |
| Lisdexamfetamine Dimesylate | 17 | $4,690 |
| Vilazodone Hcl | 52 | $4,302 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 29 | $2,989 |
| Adderall XrDextroamphetamine/Amphetamine | 12 | $2,541 |
| Olanzapine | 16 | $2,438 |
| Aripiprazole | 26 | $1,535 |
| Clonazepam | 109 | $1,139 |
| Duloxetine Hcl | 91 | $1,093 |
| Bupropion XlBupropion Hcl | 52 | $1,060 |
| Quetiapine Fumarate | 46 | $967 |
| Trazodone Hcl | 64 | $893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $448 | $15,23929 claims |
| Almatica Pharma LLCSertraline Hcl | $30 | $19425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few child & adolescent psychiatry providers in New Hampshireon file to place this against a meaningful peer group, so we don't.
Other child & adolescent psychiatry in Manchester
- Walter WingateManchester$309
- Kenneth LernerManchester$24
- Craig DonnellyLebanon$8K
- Arun KrishnanNashua$3K
- Rita Gelsomini GruberPortsmouth$2K
- Allan MendellNashua$2K
- Robert KaladishAmherst$410
- Ilene SpitzerPortsmouth$249
- Ellen SchleferRochester$186
- James McGovernHampstead$113
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.